N. Colombo, et al.: ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. In: International Journal of Gynecological Cancer. Band29 (2019), S.728–760, doi:10.1136/ijgc-2019-000308.
LE Dockery, CC Gunderson, KN Moore: Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. In: OncoTargets and Therapy. Volume 10, Juni 2017, S.3029–3037, doi:10.2147/ott.s114714.
Coleman RL, et al.: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. In: Lancet. Band390, Nr.10106, 28. Oktober 2017, S.1949–1961, doi:10.1016/S0140-6736(17)32440-6, PMID 28916367, PMC 5901715 (freier Volltext).